dll4notch信号通路相关蛋白在非小细胞肺癌中的表达及初步结构生物学研究word格式论文.docx

ABSTRACTBackgroundNon-small cell lung cancer (NSCLC) is one of the most deadly and common malignancy tumors, threatening people’s health all over the world. In the past 50 years, the incidence and the mortality of lung cancer rise rapidly, especially in the developed countries. The number of male patients, dying of lung caner, ranks first among all kinds of malignancy tumors. Among the different kinds of NSCLC, the percentage of adenocarcinoma is the largest. However, due to its late-found and fast transfering, there is little chance for most patients to be treated by surgerical methods. What is more sadness is that the chemotherapy and radiotherapy are insensitive to the most patients either. Thus, all the treatment methods of lung cancer are not satisfied in general.Recently, some experts found Angiogenesis in the newborn solid tumors. They thought it’s helpful to restrain the growth of tumor by blocking its angiogenesis. This angiogenesis repressed by drugs, will block the blood and supplies to the solid tumor. The drugs, designed according to this theory, have been used into the clinical, such as the Gefitinib and Tarceva (Epidermal Growth Factor Receptor blocker), Cetuximab (the monoclone antibody of EGFR), Bevacizumab (VEGF, vascular endothelial growth factor Blocker). All these drugs have brought great benefits to the patients who are suffering none small cell lung cancer.However, the data-based medicine shows that all these drugs mentioned above were not as sufficient as expected. Late research found that the DLL4/Notch pathway plays a great role during the solid tumor angiogenesis as well. And DLL4/Notch pathway couldhave interaction with the EGFR，LEF1 and VEGF signal pathway at the crossing-talk pointTLE1 during angiogenesis.Therefore, it brings us the following thoughts. Could DLL4 overexpressed in none small cell lung cancer related to the angiogenesis of lung cancer? How could TLE1mediate the EGFR，LEF1 and DLL4/Notch pathway? What is the structure bas